U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Endometrial Adenocarcinoma

MedGen UID:
1714709
•Concept ID:
C5237060
•
Neoplastic Process
Synonyms: Refractory Endometrial Adenocarcinoma, NOS; Refractory Endometrial Adenocarcinoma, Not Otherwise Specified

Definition

Endometrial adenocarcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V
Expert Rev Anticancer Ther 2022 Apr;22(4):383-400. Epub 2022 Apr 7 doi: 10.1080/14737140.2022.2039123. PMID: 35260027Free PMC Article
Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery.
Monk BJ, Surwit EA, Alberts DS, Graham V
Semin Oncol 1988 Jun;15(3 Suppl 4):27-31. PMID: 3134695
Recurrent stage I endometrial carcinoma: results of treatment and prognostic factors.
Mandell LR, Nori D, Hilaris B
Int J Radiat Oncol Biol Phys 1985 Jun;11(6):1103-9. doi: 10.1016/0360-3016(85)90056-2. PMID: 3997592

Recent clinical studies

Etiology

Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS; Southwest Oncology Group
Gynecol Oncol 2005 Mar;96(3):610-5. doi: 10.1016/j.ygyno.2004.11.024. PMID: 15721401
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, Potkul RK, Fine BA, Hannigan EV, Alberts DS
Gynecol Oncol 1999 Sep;74(3):432-5. doi: 10.1006/gyno.1999.5461. PMID: 10479505

Therapy

Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS; Southwest Oncology Group
Gynecol Oncol 2005 Mar;96(3):610-5. doi: 10.1016/j.ygyno.2004.11.024. PMID: 15721401
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, Potkul RK, Fine BA, Hannigan EV, Alberts DS
Gynecol Oncol 1999 Sep;74(3):432-5. doi: 10.1006/gyno.1999.5461. PMID: 10479505
A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinoma.
Kavanagh JJ, Saul PB, Wharton JT, Rutledge FN
Gynecol Oncol 1987 Feb;26(2):236-9. doi: 10.1016/0090-8258(87)90279-4. PMID: 3804040

Clinical prediction guides

Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, Potkul RK, Fine BA, Hannigan EV, Alberts DS
Gynecol Oncol 1999 Sep;74(3):432-5. doi: 10.1006/gyno.1999.5461. PMID: 10479505

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...